RT Journal Article
T1 Present and future management of viral hepatitis.
A1 González Grande, Rocío
A1 Santaella Leiva, Inmaculada
A1 López Ortega, Susana
A1 Jiménez Pérez, Miguel
K1 Diagnosis
K1 Hepatitis viral
K1 Inhibiting recycling
K1 Treatment
K1 Trend direct-acting antivirals
AB Viral hepatitis can result in important morbidity and mortality, with its impact on health conditioned by the specific type of hepatitis, the geographical region of presentation and the development and access to new drugs, among other factors. Most acute presentation forms are self-limiting and may even go unnoticed, with just a small percentage of cases leading to acute liver failure that may necessitate transplantation or even cause the death of the patient. However, when they become chronic, as in the case of hepatitis B virus and C virus, unless they are diagnosed and treated adequately they may have severe consequences, like cirrhosis or hepatocarcinoma. Understanding of the mechanisms of transmission, the pathogenesis, the presence of vaccinations and the development over recent years of new highly-efficient, potent drugs have meant that we are now faced with a new scenario in the management of viral hepatitis, particularly hepatitis B virus and hepatitis C virus. The spectacular advances in hepatitis C virus treatment have led the World Health Organization to propose the objective of its eradication by 2030. The key aspect to achieving this goal is to ensure that these treatments reach all the more vulnerable population groups, in whom the different types of viral hepatitis have a high prevalence and constitute a niche that may perpetuate infection and hinder its eradication. Accordingly, micro-elimination programs assume special relevance at the present time.
YR 2021
FD 2021
LK https://hdl.handle.net/10668/24439
UL https://hdl.handle.net/10668/24439
LA en
DS RISalud
RD Apr 6, 2025